DYRK1B and ovarian carcinoma: Finally, we found that inhibition of DYRK1B with AZ191 enhanced the cytotoxic effect of doxorubicin in liposarcoma cells, which is consistent with previous reports that DYRK1B inhibitor sensitized both ovarian cancer cell lines and patient ascites derived primary cells to chemotherapy drug cisplatin [42, 51].